

To: [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@bayer.com; [redacted]@bayer.com; [redacted]@bayer.com; [redacted]@bayer.com; [redacted]@bayer.com; [redacted]@bayer.com; [redacted]@bayer.com; [redacted]@bayer.com; [redacted]@bayer.com; [redacted]@curevac.com; [redacted]@curevac.com; [redacted]@curevac.com

From: [redacted]  
Sent: Mon 3/15/2021 3:25:28 PM  
Subject: Presentation from Curevac follow up / Thursday 11 March, 2021  
Received: Mon 3/15/2021 3:27:04 PM  
[CureVac's COVID-19 vaccine Netherlands followup 11March2021.pdf smime.p7s](#)

Dear [redacted] and Team,

Thank you for the time on the meeting on Thursday. Please find attached the Presentation we shared with you. We incorporate the current numbers to the Netherlands, too. You'll find them on the last slide.

One remark to the options for shipment. Even if we asked you about the preferred option for the Dutch team on the shipment option, I have to make the point that we will base our final decision for the option, which ensure the most efficient delivery to the member states. Netherlands preference will be included into the assessment but would not be the only consideration for the decision. Please let me know if you have any question to that.

We will follow-up with the question on the boostability of convalescent patients and the temperature logger question. As discussed we will internally assess your procedures to draw doses from the multi vial and how we can support you with testing your syringes. The material comparability testing was already agreed.

With best regards  
[redacted]

**CureVac AG**  
Friedrich-Miescher-Str. 15 | 72076 Tübingen | Deutschland  
t: +49 [redacted]  
f: +49 [redacted]  
e: [redacted]@curevac.com

[www.curevac.com](http://www.curevac.com)

[redacted]

Register of companies: HRB 754041, Stuttgart District Court

[redacted]

**Confidentiality Note:** This e-mail and any attachments thereto contain confidential information. If you are not the intended recipient, please inform the sender accordingly and delete this e-mail and any attachments thereto from your system. Please understand that any unauthorized use of this e-mail and/or its attachments, including but not limited to its duplication and disclosure to third parties, is prohibited. Thank you for your cooperation.  
**Security Note:** Please note that e-mail is not a safe way to communicate. Although we have implemented processes as a part of our IT quality management, which are continuously kept up to date and which aim to prevent our e-mails from being negatively altered (i.e. by viruses, malware, spyware), given the nature of the Internet we are not able to completely exclude such negative alteration. Therefore, please take all steps you deem necessary to verify the security of this e-mail including its attachments.